HALO
Halozyme Therapeutics Inc
110.40$
+0.5%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -22.7% | +26.5% | -56.9% | +106.8% | +54.7% | -13.6% | -35.3% | +79.1% | +22.6% | -17.8% | +33.8% | – | |
| – | +0.5% | -2.2% | +0.6% | -8.1% | +9.3% | -8.1% | +9.3% | -8.7% | +30.7% | +26.4% | +0.7% | – | |
| – | +3.2% | +2.2% | -4.1% | +32.8% | -8.9% | -6.9% | +13.9% | 0.0% | +36.3% | +0.4% | +6.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -169.1% | – | -3,011.7% | – | – | – | -934.1% | – | – | – | – | – | |
| – | -11.8% | +36.6% | -27.2% | -41.2% | +101.2% | -68.9% | +64.5% | +93.9% | -52.9% | +162.2% | +11.5% | – | |
| – | -90.1% | +897.2% | -49.2% | +298.4% | – | -406.7% | – | +137.8% | -467.9% | -99.6% | +2,078.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -99.8% | -100.0% | – | -51,224.7% | – | – | -87.0% | -100.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -6,194.1% | -99.8% | – | +95.7% | -1,427.6% | -98.7% | +8,902.3% | -92.5% | – | -100.7% | +20,126.3% | – | |
| – | -393.7% | – | -49.8% | -244.4% | – | – | -289.3% | – | -179.9% | – | -184.1% | – | |
| – | -22.9% | +26.2% | -57.7% | +114.0% | +54.1% | -12.6% | -36.0% | +78.9% | +23.9% | -19.0% | +34.2% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.